Last reviewed · How we verify

Neu-P11

Neurim Pharmaceuticals Ltd. · Phase 2 active Small molecule

Neu-P11 (Piromelatine) is a novel melatonin receptor agonist and serotonin 5-HT2C receptor antagonist in development by Neurim Pharmaceuticals for mild Alzheimer's disease and primary insomnia. It has completed Phase 2 trials and is currently in Phase 3 for Alzheimer's disease. The drug shows promise in improving cognitive function and sleep quality.

At a glance

Generic nameNeu-P11
Also known asMelatonin agonist, there are no other names
SponsorNeurim Pharmaceuticals Ltd.
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.